When should a quantitative serum glutamic acid decarboxylase‑65 (GAD65) antibody assay be ordered and how is a positive result interpreted in evaluating autoimmune conditions such as type 1 diabetes mellitus or stiff‑person syndrome?

When to Order GAD65 Antibody Testing and How to Interpret Results

Indications for GAD65 Antibody Testing

Order quantitative serum GAD65 antibody testing in adults with newly diagnosed diabetes when there is phenotypic overlap between type 1 and type 2 diabetes and uncertainty about diabetes classification. 1

Specific Clinical Scenarios for Diabetes Evaluation

Order GAD65 antibody testing when ≥2 of the following high-risk features are present in an adult with diabetes: 2

• Age <50 years at diagnosis
• Acute hyperglycemic symptoms with unintended weight loss
• BMI <25 kg/m²
• Personal or family history of autoimmune disease

Do not order islet autoantibodies, including GAD65, for routine diagnosis of diabetes. 1 The diagnosis of diabetes itself is made by standard glycemic criteria; autoantibody testing serves to classify the type of diabetes, not to diagnose hyperglycemia. 1

Neurological Indications

Order GAD65 antibody testing when evaluating for: 3, 4

• Stiff-person syndrome (SPS) or stiff-limb syndrome
• Progressive encephalomyelitis with rigidity and myoclonus
• Limbic encephalitis
• Refractory epilepsy or focal seizures
• Cerebellar ataxia of unclear etiology

GAD65 antibodies are detected in 98% of patients with stiff-person syndrome, with titers typically exceeding 20 nmol/L in 96% of cases. 3 This contrasts sharply with type 1 diabetes, where 85% of positive GAD65 values are ≤20 nmol/L. 3

Screening in At-Risk Populations

Screening for GAD65 and other islet autoantibodies can be offered to first-degree relatives of individuals with type 1 diabetes, but is recommended primarily in research settings until cost-effective strategies and effective prevention therapies become available. 1

---

Interpretation of Positive GAD65 Results

In the Context of Diabetes

A single positive GAD65 antibody in an adult with strong clinical features of autoimmune diabetes (young age, acute symptoms, low BMI, weight loss) is likely a true positive and supports latent autoimmune diabetes in adults (LADA). 2

Multiple positive islet autoantibodies (GAD65 plus IA-2, ZnT8, or insulin autoantibodies) strongly confirm autoimmune diabetes and predict more rapid decline in beta-cell function. 2 Patients with two or more islet autoantibodies have a 70% risk of progressing to clinical diabetes within 10 years, compared to only 15% with a single autoantibody. 1

Titer-Based Interpretation for LADA

• Higher GAD65 titers are associated with faster progression to insulin dependence. 2
• Patients with GAD65 titers >250 IU/mL or multiple autoantibodies should receive earlier insulin therapy to achieve beta-cell rest and preserve function. 2
• Approximately 80% of adults with type 1 diabetes are GAD65-positive, with 85% of these having titers ≤20 nmol/L. 3

Clinical Phenotype Correlation

GAD65-positive adults initially presenting with a type 2 diabetes phenotype represent 5–10% of such patients and have latent autoimmune diabetes (LADA). 1, 2 These individuals progress to insulin dependence faster than autoantibody-negative patients. 1

ECL-GAD65 antibody-positive LADA patients are leaner, have poorer beta-cell function, and resemble type 1 diabetes patients, whereas ECL-GAD65 antibody-negative patients share phenotypic features with type 2 diabetes. 5

In the Context of Neurological Disease

Extremely high GAD65 titers (often >100-fold higher than in diabetes) strongly suggest neurological autoimmunity, particularly stiff-person syndrome. 3, 6 In SPS, 96% of patients have titers exceeding 20 nmol/L, and free GAD65 as well as GAD65-GADA immune complexes are significantly elevated compared to healthy controls. 6

GAD65 antibody is not highly predictive of paraneoplastic neurological syndromes, though diverse cancer types have been occasionally reported. 4 Responses to immunotherapy in GAD65-associated neurological disorders are variable, with approximately 50% of patients improving. 4

Associated Autoimmune Conditions

Screen for coexisting autoimmune disorders in all GAD65-positive patients. 2, 4 Approximately 70% of patients with GAD65 neurological autoimmunity have one or more of the following: 4

• Type 1 diabetes mellitus
• Autoimmune thyroid disease
• Pernicious anemia
• Celiac disease
• Addison's disease

In the diabetes context, 76% of stiff-person syndrome patients and 59% of type 1 diabetes patients have additional thyrogastric autoantibodies. 3

---

Testing Algorithm

For Adults with Newly Diagnosed Diabetes

1. Assess clinical phenotype for high-risk features (age <50 years, acute symptoms, BMI <25 kg/m², autoimmune history). 2
2. If ≥2 high-risk features present: Order GAD65 antibody testing. 2
3. If GAD65 is positive: Diagnose LADA provided the patient has remained insulin-independent for ≥6 months. 2
4. If GAD65 is negative but suspicion remains high: Test IA-2 and ZnT8 antibodies. 2
5. If any autoantibody is positive: Confirm autoimmune diabetes and initiate appropriate management. 2

For Suspected Neurological Autoimmunity

Use ELISA as the sole diagnostic method for GAD65-related neurological disease rather than immunoblot. 7 ELISA demonstrates 100% sensitivity and 91% specificity for GAD65-related neurological disease, compared to immunoblot's 43% sensitivity and 76% specificity. 7

---

Critical Pitfalls to Avoid

Do not rely on BMI alone to exclude LADA—obesity does not rule out autoimmune diabetes. 2

Do not assume a normal C-peptide excludes LADA—autoantibody testing remains mandatory when clinical suspicion exists. 2 C-peptide measurement is not required for initial LADA diagnosis and should only be used in insulin-treated patients to assess residual beta-cell function. 2

Do not use sulfonylureas in GAD65-positive patients, as they accelerate beta-cell exhaustion in autoimmune diabetes. 2

Do not delay insulin initiation in high-risk patients with high GAD65 titers, multiple antibodies, or rapid glycemic worsening. 2

Recognize that 1–2% of healthy individuals may have a single islet autoantibody and are at low risk of diabetes, whereas multiple autoantibodies confer substantially higher risk. 1